[December 18, 2014] |
|
Research and Markets: Metastatic Melanoma - Pipeline Review, H1 2014
Research and Markets (http://www.researchandmarkets.com/research/9qwt9g/metastatic)
has announced the addition of the "Metastatic
Melanoma - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic
development for Metastatic Melanoma, complete with comparative analysis
at various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for
Metastatic Melanoma and special features on late-stage and discontinued
projects.
Reasons to buy
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
andcreate effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Metastatic Melanoma
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Metastatic Melanoma pipeline depth and focus of Indication therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
Bristol-Myers Squibb Company
-
F. Hoffmann-La Roche Ltd.
-
Vical Incorporated
-
Amgen Inc.
-
Sanofi
-
AstraZeneca PLC
-
GlaxoSmithKline plc
-
Genentech, Inc.
-
MedImmune, LLC
-
Plexxikon Inc.
-
Delcath Systems, Inc.
-
Millennium Pharmaceuticals, Inc.
-
Novartis AG
-
Eisai Co., Ltd.
-
Ono Pharmaceutical Co., Ltd.
-
Pfizer Inc.
-
Celgene Corporation
-
Bayer AG
-
Incyte Corporation
-
Luitpold Pharmaceuticals, Inc.
-
Merck KGaA
-
Celldex Therapeutics, Inc.
-
Momenta Pharmaceuticals, Inc.
-
AVAX Technologies, Inc.
-
Oncolytics Biotech Inc.
-
Antisoma plc
-
Progen Pharmaceuticals Limited
-
HanAll Biopharma Co., Ltd.
-
Provectus Biopharmaceuticals, Inc.
-
BioAlliance Pharma SA
For more information visit http://www.researchandmarkets.com/research/9qwt9g/metastatic
[ Back To TMCnet.com's Homepage ]
|